Observational studyLeukemia2021

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.

Alessandro M Vannucchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.